| abstract |
The present invention provides novel biomarkers that segregate with measures of clinical severity of spinal muscular atrophy. In particular, biomarkers in the plasma and urine that can be used to predict or assess severity of SMA or confirm diagnosis of SMA in a patient are disclosed. Methods of using such biomarkers to screen potential therapeutics and monitor efficacy of a therapeutic intervention in a patient are also described. |